0001209191-21-005158.txt : 20210125
0001209191-21-005158.hdr.sgml : 20210125
20210125174108
ACCESSION NUMBER: 0001209191-21-005158
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210121
FILED AS OF DATE: 20210125
DATE AS OF CHANGE: 20210125
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Carter Martha J.
CENTRAL INDEX KEY: 0001213040
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33451
FILM NUMBER: 21550967
MAIL ADDRESS:
STREET 1: C/O AEGERION PHARMACEUTICALS, INC.
STREET 2: 89 HEADQUARTERS PLAZA, SUITE 1212
CITY: MORRISTOWN
STATE: NJ
ZIP: 07960
FORMER NAME:
FORMER CONFORMED NAME: CARTER MARTHA J
DATE OF NAME CHANGE: 20030106
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ALBIREO PHARMA, INC.
CENTRAL INDEX KEY: 0001322505
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10 POST OFFICE SQUARE
STREET 2: SUITE 502 SOUTH
CITY: BOSTON
STATE: MA
ZIP: 02109
BUSINESS PHONE: 857-415-4774
MAIL ADDRESS:
STREET 1: 10 POST OFFICE SQUARE
STREET 2: SUITE 502 SOUTH
CITY: BOSTON
STATE: MA
ZIP: 02109
FORMER COMPANY:
FORMER CONFORMED NAME: Biodel Inc
DATE OF NAME CHANGE: 20050331
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-01-21
0
0001322505
ALBIREO PHARMA, INC.
ALBO
0001213040
Carter Martha J.
C/O ALBIREO PHARMA, INC.
10 POST OFFICE SQUARE, SUITE 1000
BOSTON
MA
02109
0
1
0
0
Chief Regulatory Officer
Common Stock
2021-01-21
4
A
0
5500
0.00
A
5500
D
Stock Option (right to buy)
34.88
2021-01-21
4
A
0
23700
0.00
A
2031-01-20
Common Stock
23700
23700
D
Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% of the shares on January 21, 2022, with the remainder vesting in equal installments every three months thereafter beginning on April 21, 2022 and ending on January 21, 2025.
Represents 5,500 restricted stock units.
This option vests as to 25% of the shares on January 21, 2022, with the remainder vesting in equal installments every three months thereafter beginning on April 21, 2022 and ending on January 21, 2025.
/s/ Jason Duncan, Attorney-in-fact
2021-01-25